Skip to main content
PepStack
Wiki · Profile

GHRP-2

KP-102 · Growth Hormone Releasing Peptide 2

GH SecretagoguePreclinical
From$2.02/mgCompare prices
MW
818g/mol
Formula
C45H55N9O6

GHRP-2, also known as pralmorelin, is a synthetic growth hormone-releasing peptide that belongs to a class of compounds designed to stimulate endogenous growth hormone secretion. Researchers primarily study GHRP-2 for its potential role in diagnosing growth hormone deficiencies and its effects on increasing serum insulin-like growth factor-1 (IGF-1) levels. Key findings from studies indicate that GHRP-2 can significantly elevate plasma growth hormone levels in healthy individuals, while its efficacy may be reduced in those with growth hormone deficiencies. Additionally, GHRP-2 has been shown to maintain its growth hormone-releasing activity across various age groups, although its effectiveness diminishes with advancing age. Current research continues to explore its applications in clinical settings, particularly in relation to growth hormone-related disorders.

Chemical Profile

Chemical Profile

Chemical structure
Chemical Structure
FormulaC45H55N9O6
Molecular Weight818 g/mol
CAS Number158861-67-7
PubChem CID6918245
ChEMBL IDCHEMBL4297297

Half-Life

SCSubcutaneous

~1-2 hours

IMIntramuscular

~1-2 hours

IVIntravenous

~30 minutes

POOral

Poor bioavailability

The half-life can vary based on individual metabolic factors and the specific formulation used.

Mechanism

Mechanism of Action

GHRP-2 acts primarily through specific growth hormone secretagogue receptors (GHS-R), which are G-protein-coupled receptors (GPCRs) that stimulate the release of growth hormone (GH) from somatotropes in the anterior pituitary. The signaling pathways involved likely include the activation of phospholipase C (PLC) and subsequent inositol trisphosphate (IP3) production, leading to calcium mobilization and enhanced GH secretion, although the precise mechanisms remain incompletely understood. Additionally, GHRP-2 may counteract somatostatinergic activity, further promoting GH release.

Research

66 Research Publications

2,090

Total Citations

32

Human/RCT

2.3

Avg. Influence

2025

Latest

Sort
Filter
#01

Anti-inflammatory effect of the ghrelin agonist growth hormone-releasing peptide-2 (GHRP-2) in arthritic rats.

AnimalInfluence7.0
182
The study demonstrated that GHRP-2 administration reduced arthritis symptoms and serum IL-6 levels in arthritic rats, suggesting an anti-inflammatory effect.
100 mcgnot specified(human)not specified1 microg/kg/hinfusion(human)5 days1 microg/kg/hinfusion(human)21 hours1 microg/kgi.v.(children)not specified100 microg/kgnot specified(rats)8 days10 nMnot specified(ovine)not specified
PubMed
#02

GH releasing peptides--structure and kinetics.

HumanInfluence9.0
173
The study demonstrated that GHRP-2, along with other GHRPs, effectively releases growth hormone in humans, outperforming GHRH in efficacy.
100 mcgnot specified(human)not specified1 microg/kg/hinfusion(human)5 days1 microg/kg/hinfusion(human)21 hours1 microg/kgi.v.(children)not specified100 microg/kgnot specified(rats)8 days10 nMnot specified(ovine)not specified
PubMed
#03

Chicken ghrelin and growth hormone-releasing peptide-2 inhibit food intake of neonatal chicks.

AnimalInfluence5.0
161
Researchers observed that GHRP-2 and chicken ghrelin significantly inhibited food intake in neonatal chicks, indicating their role as GHS receptor agonists.
100 mcgnot specified(human)not specified1 microg/kg/hinfusion(human)5 days1 microg/kg/hinfusion(human)21 hours1 microg/kgi.v.(children)not specified100 microg/kgnot specified(rats)8 days10 nMnot specified(ovine)not specified
PubMed
#04

The somatotropic axis in critical illness: effect of continuous growth hormone (GH)-releasing hormone and GH-releasing peptide-2 infusion.

Human
155
Researchers observed that continuous infusion of GHRP-2 significantly increases GH secretion and serum IGF-I levels in critically ill adults without altering cortisol levels.
100 mcgnot specified(human)not specified1 microg/kg/hinfusion(human)5 days1 microg/kg/hinfusion(human)21 hours1 microg/kgi.v.(children)not specified100 microg/kgnot specified(rats)8 days10 nMnot specified(ovine)not specified
PubMed
#05

The combined administration of GH-releasing peptide-2 (GHRP-2), TRH and GnRH to men with prolonged critical illness evokes superior endocrine and metabolic effects compared to treatment with GHRP-2 alone.

HumanInfluence3.0
134
The study demonstrated that combined administration of GHRP-2, TRH, and GnRH in critically ill men enhances endocrine and metabolic responses compared to GHRP-2 alone.
100 mcgnot specified(human)not specified1 microg/kg/hinfusion(human)5 days1 microg/kg/hinfusion(human)21 hours1 microg/kgi.v.(children)not specified100 microg/kgnot specified(rats)8 days10 nMnot specified(ovine)not specified
PubMed
#06

Effects of GHRP-2 and hexarelin, two synthetic GH-releasing peptides, on GH, prolactin, ACTH and cortisol levels in man. Comparison with the effects of GHRH, TRH and hCRH.

HumanInfluence3.0
88
The study demonstrated that GHRP-2 and Hexarelin induce similar GH responses in humans, with both showing slight stimulatory effects on prolactin, ACTH, and cortisol levels.
1 micrograms/kgintravenous(children)1 microg/kg/hsubcutaneous(human)270 minutes1 microg/kgintravenous(human)2 micrograms/kgintravenous(human)2, 10, 30 and 100 microg/kg body weightintravenous(swine)30 microg/kg BWsubcutaneous(swine)30 days
PubMed
#07

High-throughput screening for various classes of doping agents using a new 'dilute-and-shoot' liquid chromatography-tandem mass spectrometry multi-target approach.

In VitroInfluence1.0
79
The study demonstrated a new multi-target approach for doping agent screening that successfully detects GHRP-2 metabolites in urine at low concentration levels.
100 mcgnot specified(human)not specified1 microg/kg/hinfusion(human)5 days1 microg/kg/hinfusion(human)21 hours1 microg/kgi.v.(children)not specified100 microg/kgnot specified(rats)8 days10 nMnot specified(ovine)not specified
PubMed
#08

Pituitary responsiveness to GH-releasing hormone, GH-releasing peptide-2 and thyrotrophin-releasing hormone in critical illness.

HumanInfluence1.0
70
Researchers observed that GHRP-2 significantly enhances GH secretion in critically ill patients, showing a greater response than GHRH alone.
100 mcgnot specified(human)not specified1 microg/kg/hinfusion(human)5 days1 microg/kg/hinfusion(human)21 hours1 microg/kgi.v.(children)not specified100 microg/kgnot specified(rats)8 days10 nMnot specified(ovine)not specified
PubMed
#09

Ghrelin receptor agonist GHRP-2 prevents arthritis-induced increase in E3 ubiquitin-ligating enzymes MuRF1 and MAFbx gene expression in skeletal muscle.

AnimalInfluence3.0
61
The study demonstrated that GHRP-2 prevents arthritis-induced increases in E3 ubiquitin-ligating enzymes in skeletal muscle of rats.
100 mcgnot specified(human)not specified1 microg/kg/hinfusion(human)5 days1 microg/kg/hinfusion(human)21 hours1 microg/kgi.v.(children)not specified100 microg/kgnot specified(rats)8 days10 nMnot specified(ovine)not specified
PubMed
#10

The effect of GH-releasing peptide-2 (GHRP-2 or KP 102) on GH secretion from primary cultured ovine pituitary cells can be abolished by a specific GH-releasing factor (GRF) receptor antagonist.

In VitroInfluence5.0
61
The study demonstrated that KP 102 (GHRP-2) significantly increases GH secretion from primary cultured ovine pituitary cells in a dose-dependent manner, acting through a different receptor than earlier GH-releasing peptides.
100 mcgnot specified(human)not specified1 microg/kg/hinfusion(human)5 days1 microg/kg/hinfusion(human)21 hours1 microg/kgi.v.(children)not specified100 microg/kgnot specified(rats)8 days10 nMnot specified(ovine)not specified
PubMed
Safety

Safety & Handling

Research Gaps

The specific mechanisms by which GHRP-2 and other GHRPs counteract somatostatinergic activity remain unclear, and the potential existence of a natural GHRP-like ligand has not yet been identified. Additionally, while some studies indicate the efficacy of GHRP-2 in increasing IGF-1 levels, there is a lack of comprehensive long-term human trials assessing the safety and sustained effects of GHRP-2 therapy in various populations, particularly in those with GH deficiency or other hyposecretory states.

Solubility

GHRP-2 is soluble in water and DMSO.

Storage & Handling

Lyophilized

Stable for 2+ years at -20°C, 12 months at 4°C

Reconstituted

Use within 14 days when refrigerated at 4°C

Avoid

Avoid repeated freeze-thaw cycles, direct light

Solvent

Bacteriostatic water or sterile saline recommended

Safety information is derived from published research and may not reflect all known risks. This is not medical advice.

Legal Status

Legal Status

🇩🇪DE

Not approved as a medicinal product. Not a controlled substance. Sale as research chemical is a legal grey area.

🇺🇸US

Not approved by the FDA as a medicinal product. Not scheduled by the DEA.

🇦🇺AU

Not approved by the TGA as a therapeutic good.

🇬🇧UK

Not approved by the MHRA as a medicinal product.

Legal status information is provided for general reference only and may not reflect the most current regulatory changes. Always verify with official government sources before making any decisions.

Community Insights

Community Insights

Publications per Year

48 total
1
93
1
94
2
95
4
96
4
97
4
98
2
99
3
00
1
01
2
02
3
04
4
05
1
07
4
09
3
10
1
11
1
13
1
14
3
15
1
16
1
17
1
20
Pricing

Price Comparison

  • BESTResearch Peptides UKUK
    5mg
    $10.10
    Price/mg
    $2.02/mg
  • Biolab ShopUS
    10mg
    $22.67
    Price/mg
    $2.27/mg
  • Research Peptides UKUK
    10mg
    $24.13
    Price/mg
    $2.41/mg
  • Ruo BioUS
    5mg
    $14.00
    Price/mg
    $2.80/mg
  • MoglabsUS
    5mg
    $16.00
    Price/mg
    $3.20/mg

Top 5 of 34 offers from 29 vendors. Prices updated daily.

See all GHRP-2 prices
Mechanism

Tools

Mechanism

Related Peptides

Track GHRP-2 in PepStack

Log your research cycles, set reminders and visualize serum levels.

Legal Disclaimer

This page is for informational and research purposes only. All information is based on published scientific literature and does not constitute medical advice, diagnosis, or treatment recommendations. Many substances listed may not be approved for human use and may be subject to drug regulation laws (e.g., AMG in Germany, FDA in the US). PepStack does not encourage the use of any substance on humans. Always consult a qualified healthcare professional before making any health-related decisions. Use of this information is entirely at your own risk. PepStack assumes no liability for the accuracy, completeness, or timeliness of the content provided. Full disclaimer